CARLSBAD, Calif. – November 8, 2010 – Life Technologies Corporation (NASDAQ: LIFE) today announced that it has signed a strategic licensing agreement with Biopredic International for exclusive rights to produce and supply cryopreserved HepaRG® cells worldwide and to produce and supply other formats of HepaRG® cells within North America.  The availability of HepaRG® cells will enable pharmaceutical companies to screen small molecules in a metabolically competent system earlier in the drug development process. This approach has the potential to identify and terminate potentially dangerous or unsuccessful compounds more rapidly than current methods, thus leading to faster development of safer and more effective drugs. 

HepaRG® is a human hepatoma cell line that maintains many characteristics of primary human hepatocytes (cells that make up 70-80% of the liver) and is capable of indefinite propagation of a single population of cells.  This unique combination of traits makes HepaRG® cells a unique in vitro system for drug metabolism and toxicity studies. 

ADME (absorption, distribution, metabolism, excretion) plays an ever increasing role in the drug discovery process. Traditionally, ADME tools were applied at the end of the drug development pipeline.  However, a paradigm shift has begun moving ADME testing to earlier stages resulting in removal of molecules with poor ADME properties earlier from the drug development pipeline.  A Business Insights report entitled, Early Stage Drug Safety Strategies and Risk Management communicates existing challenges in the industry, which include instances where significant investment has been made only for failure to occur in the late stages of drug development, or after a drug has been commercialized.

HepaRG® meets our customers’ need for a reproducible, metabolically active platform for higher throughput compound screening,” said Dr. Chris Armstrong, Head of Discovery & ADME/Tox Systems at Life Technologies.  The lack of donor variability makes these cells ideally suited for drug discovery and screening studies where the goal is to evaluate many compounds against a common reference. Customers will now be able to compare the metabolic profile of a large collection of compounds without having to account for the donor variability present in hepatocytes.”

“We are pleased to partner with Life Technologies to provide HepaRG® as part of their broad portfolio of ADME/Toxicology products and services,” said Dr. Christophe Chesne, CEO of Biopredic International. “HepaRG cells, which we re originally identified by Sylvie Rumin & Philippe Gripon in Dr. Christiane Guillouzo’s laboratory at the Institut National de la Santé et de la Recherche Médicale (INSERM),  respond and function like typical primary human hepatocytes across a range of applications, which makes them a powerful screening tool for metabolism studies and a significant addition to Life Technologies’ current offering.”

About Life Technologies
Life Technologies Corporation (NASDAQ: LIFE) is a global biotechnology tools company dedicated to improving the human condition. Our systems, consumables and services enable researchers to accelerate scientific exploration, driving to discoveries and developments that make life even better. Life Technologies customers do their work across the biological spectrum, working to advance personalized medicine, regenerative science, molecular diagnostics, agricultural and environmental research, and 21st century forensics. Life Technologies had sales of $3.3 billion in 2009, employs approximately 9,000 people, has a presence in approximately 160 countries, and possesses a rapidly growing intellectual property estate of approximately 3,900 patents and exclusive licenses. Life Technologies was created by the combination of Invitrogen Corporation and Applied Biosystems Inc., and manufactures both in-vitro diagnostic products and research use only-labeled products. For more information on how we are making a difference, please visit our website:

Safe Harbor Statement

This press release includes forward-looking statements about our anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies' plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words "believe," "plan," "intend," "anticipate," "target," "estimate," "expect" and the like, and/or future tense or conditional constructions ("will," "may," "could," "should," etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Life Technologies with the Securities and Exchange Commission. Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.

HepaRG® cells are For Research Use Only.  Not intended for any animal or human therapeutic or diagnostic use.

Life Technologies Contact   
Lauren Lum